TG Therapeutics, Inc. (TGTX): Price and Financial Metrics

TG Therapeutics, Inc. (TGTX): $13.32

0.12 (-0.89%)

POWR Rating

Component Grades








Add TGTX to Watchlist
Sign Up

Industry: Biotech




#47 of 357

in industry

TGTX Price/Volume Stats

Current price $13.32 52-week high $35.67
Prev. close $13.44 52-week low $6.46
Day low $13.19 Volume 2,402,800
Day high $13.56 Avg. volume 4,981,284
50-day MA $16.24 Dividend yield N/A
200-day MA $16.05 Market Cap 2.02B

TGTX Stock Price Chart Interactive Chart >


  • Growth is the dimension where TGTX ranks best; there it ranks ahead of 98.99% of US stocks.
  • TGTX's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • TGTX's current lowest rank is in the Stability metric (where it is better than 0.43% of US stocks).

TGTX Stock Summary

  • With a price/sales ratio of 13.49, TG THERAPEUTICS INC has a higher such ratio than 91.88% of stocks in our set.
  • As for revenue growth, note that TGTX's revenue has grown 3,676.56% over the past 12 months; that beats the revenue growth of 99.78% of US companies in our set.
  • In terms of volatility of its share price, TGTX is more volatile than 92.68% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TG THERAPEUTICS INC are SCYX, PSTV, MNTS, ORGN, and ARQT.
  • Visit TGTX's SEC page to see the company's official filings. To visit the company's web site, go to

TGTX Valuation Summary

  • In comparison to the median Healthcare stock, TGTX's EV/EBIT ratio is 1454.11% lower, now standing at -197.7.
  • TGTX's EV/EBIT ratio has moved down 192.8 over the prior 166 months.

Below are key valuation metrics over time for TGTX.

Stock Date P/S P/B P/E EV/EBIT
TGTX 2023-12-29 13.6 15.7 -99.8 -197.7
TGTX 2023-12-28 14.1 16.2 -103.0 -204.0
TGTX 2023-12-27 13.6 15.7 -99.6 -197.3
TGTX 2023-12-26 13.6 15.6 -99.3 -196.6
TGTX 2023-12-22 13.6 15.6 -99.4 -196.7
TGTX 2023-12-21 13.7 15.8 -100.2 -198.5

TGTX Growth Metrics

    Its 5 year revenue growth rate is now at -0.25%.
  • The 3 year revenue growth rate now stands at 5105.26%.
  • Its 2 year price growth rate is now at -68.05%.
Over the past 49 months, TGTX's revenue has gone up $4,872,905.

The table below shows TGTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 5.025 -239.209 -238.679
2022-06-30 6.961 -271.915 -288.498
2022-03-31 7.912 -282.968 -326.485
2021-12-31 6.689 -295.634 -348.101
2021-09-30 4.406 -260.751 -342.98
2021-06-30 2.414 -250.082 -344.506

TGTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TGTX has a Quality Grade of D, ranking ahead of 7.5% of graded US stocks.
  • TGTX's asset turnover comes in at 0.005 -- ranking 411th of 681 Pharmaceutical Products stocks.
  • TMBR, ATRA, and EVOK are the stocks whose asset turnover ratios are most correlated with TGTX.

The table below shows TGTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 0.881 -27.668
2021-03-31 0.002 0.847 -42.516
2020-12-31 0.000 1.000 -36.140
2020-09-30 0.001 1.000 -86.159
2020-06-30 0.001 1.000 -22.399
2020-03-31 0.001 1.000 -12.310

TGTX Price Target

For more insight on analysts targets of TGTX, see our TGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.33 Average Broker Recommendation 1.44 (Moderate Buy)

TG Therapeutics, Inc. (TGTX) Company Bio

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.

TGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TGTX Latest Social Stream

Loading social stream, please wait...

View Full TGTX Social Stream

Latest TGTX News From Around the Web

Below are the latest news stories about TG THERAPEUTICS INC that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […]

Yahoo | December 15, 2023

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.

Yahoo | December 7, 2023

TG Therapeutics (NASDAQ:TGTX) grows 9.1% this week, taking five-year gains to 170%

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

Yahoo | December 4, 2023

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ETNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 6th Annual Evercore ISI HealthCONx Conference, being held at the Kimpton EPIC Hotel, in Miami, Florida on November 28 - 30, 2023. The fireside chat is scheduled to take place on Wednesday, November 29, 2023, at 2:10 PM ET. A live web

Yahoo | November 27, 2023

Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 6, 2023

Read More 'TGTX' Stories Here

TGTX Price Returns

1-mo -15.70%
3-mo 5.05%
6-mo 27.34%
1-year -15.16%
3-year -69.38%
5-year 168.55%
YTD -22.01%
2023 44.38%
2022 -37.74%
2021 -63.48%
2020 368.65%
2019 170.73%

Continue Researching TGTX

Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:

Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!